Showing results (271-280 of 295) with videos related to

Sort By:
Pageof 30
Drug Metabolism and Pharmacokinetics|August 17, 2011
Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patientsKeiko Maekawa, Tetsuya Hamaguchi, Yoshiro Saito, et al.
Drug Metabolism and Pharmacokinetics|December 25, 2004
Three novel single nucleotide polymorphisms in UGT1A10Mayumi Saeki, Shogo Ozawa, Yoshiro Saito, et al.
International Journal of Clinical Oncology|December 16, 2019
Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS studyToshikazu Moriwaki, Shota Fukuoka, Toshiki Masuishi, et al.
Molecular Genetics and Metabolism|July 2, 2005
Functional analysis of four naturally occurring variants of human constitutive androstane receptorShinobu Ikeda, Kouichi Kurose, Hideto Jinno, et al.
Lancet (London, England)|December 26, 2015
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 studyJames C Yao, Nicola Fazio, Simron Singh, et al.
Plos Biology|April 19, 2019
Harmonization of resting-state functional MRI data across multiple imaging sites via the separation of site differences into sampling bias and measurement biasAyumu Yamashita, Noriaki Yahata, Takashi Itahashi, et al.
The Oncologist|September 13, 2017
Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational StudyToshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, et al.
International Journal of Clinical Oncology|July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumTakahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.
International Journal of Clinical Oncology|March 4, 2026
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumRyosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, et al.
The New England Journal of Medicine|May 14, 2015
Randomized trial of TAS-102 for refractory metastatic colorectal cancerRobert J Mayer, Eric Van Cutsem, Alfredo Falcone, et al.
Pageof 30